Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 20, 2017
Reflecting on Recent Report Updates: Favorites in an Overheated Market and Other Themes
It’s been some time since we’ve updated members on our recent fair value estimate updates. Let’s take a look at the opportunities that exist in some of our favorite portfolio holdings, as well as some key themes driving recent fair value estimate changes across our coverage universe. Apr 18, 2017
United’s Passenger Debacle An Immaterial Investment Consideration
Image Source: Tomás Del Coro. The major airlines in the US have done a fantastic job capitalizing on the ongoing upswing in air travel demand, but their economically-sensitive business models remain the most operationally-leveraged out of any industry group in our coverage. This should be investors' biggest concern: A downturn in the global economy and competitive pricing pressures are far greater worries for investors than United’s recent passenger debacle. However, as with many news-oriented items (as opposed to materially-relevant, investment-related items), United's misstep is making headlines in a big way. Though the footage in this article is appalling, investors in airline stocks have much more important things to worry about, in our view. Apr 17, 2017
Which Mid-Stage Biotech Can Grow Into the Next Large Cap Biotech Behemoth?
Image Source: Steven Depolo. The biotech field is on the cutting edge of scientific research. The production of new therapies often positively affects the share price of these innovative companies as long-term revenue and earnings expectations become embedded in the stock price. Let’s take a look at several mid-stage biotechs that may grow into dominant players. Apr 17, 2017
Dividend Increases/Decreases for the Week Ending April 14
Let's take a look at companies raising/lowering their dividends this week. Apr 13, 2017
Trash As A Source of Cash and 2 New Additions to the Best Ideas Newsletter Portfolio
Image Source: thetaxhaven. We’re making a number of adjustments to the Best Ideas Newsletter portfolio. Apr 11, 2017
Three Notable Pending FDA Approvals
Image Source: Brandon Giesbrecht. The final step of the drug approval process is the filing of a new drug application (NDA), when the FDA assesses trial results before deciding if the treatment warrants marketing approval. A delay or rejection can have a meaningful impact on the equity price, so let’s dig into a few notable upcoming decisions. Apr 10, 2017
Dividend Increases/Decreases for the Week Ending April 7
Let's take a look at companies raising/lowering their dividends this week. Apr 7, 2017
Panera Eaten Up; SeaDrill’s End, Cisco’s Dividend Hike and Much More
Let’s go around the horn with recent investment-related news. Let’s say goodbye to Panera, talk about SeaDrill’s infamous demise, follow up on the Coach dividend saga, address Cisco’s payout strength and attractive valuation, update readers on Medtronic’s portfolio optimization initiatives, and try to reason through Tesla’s recent price surge. Apr 4, 2017
New Taxes? Trump’s Misstep and Seeming About-Face
Image Source: FactSet and Valuentum. News that Trump was considering new taxes, his failure to repeal Obamacare, and the seeming about-face on for-profit education regulations have put the probability of corporate tax reform in jeopardy, from where we stand. If we’re right, the implications on the market could be considerable… and not in a good way. Let’s talk about this in the context of current market valuations. Apr 4, 2017
Can Vertex Pharmaceuticals Dominate the Race to Treat Cystic Fibrosis?
Cystic Fibrosis is a rare disease that afflicts an estimated seventy-five thousand patients worldwide. Vertex Pharmaceuticals is the first to market with a combination treatment to treat a portion of the overall patient population. Will Vertex win the race to bring forth a triple therapy to treat the vast majority of those afflicted?
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353354355356357358359360 361362363364365366367368369370371372373374375376377378379380 381382383384385386387388389390391392393394395396397398399400 401402403404405406407408409410411412413414415416417418419420 421422423424425426427428429430431432433434435436437438439440 441442443444445446447448449450451452453454455456457458459460 461462463464465466467468469470471472473474475476477478479480 481482483484485486487488489490491492next The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|